FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197830587> ?p ?o ?g. }

• W3197830587 endingPage "1390" @default.
• W3197830587 startingPage "1390" @default.
• W3197830587 abstract "Safety surveillance of vaccines against COVID-19 is critical to ensure safety, maintain trust, and inform policy.To monitor 23 serious outcomes weekly, using comprehensive health records on a diverse population.This study represents an interim analysis of safety surveillance data from Vaccine Safety Datalink. The 10 162 227 vaccine-eligible members of 8 participating US health plans were monitored with administrative data updated weekly and supplemented with medical record review for selected outcomes from December 14, 2020, through June 26, 2021.Receipt of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccination, with a risk interval of 21 days for individuals after vaccine dose 1 or 2 compared with an interval of 22 to 42 days for similar individuals after vaccine dose 1 or 2.Incidence of serious outcomes, including acute myocardial infarction, Bell palsy, cerebral venous sinus thrombosis, Guillain-Barré syndrome, myocarditis/pericarditis, pulmonary embolism, stroke, and thrombosis with thrombocytopenia syndrome. Incidence of events that occurred among vaccine recipients 1 to 21 days after either dose 1 or 2 of a messenger RNA (mRNA) vaccine was compared with that of vaccinated concurrent comparators who, on the same calendar day, had received their most recent dose 22 to 42 days earlier. Rate ratios (RRs) were estimated by Poisson regression, adjusted for age, sex, race and ethnicity, health plan, and calendar day. For a signal, a 1-sided P < .0048 was required to keep type I error below .05 during 2 years of weekly analyses. For 4 additional outcomes, including anaphylaxis, only descriptive analyses were conducted.A total of 11 845 128 doses of mRNA vaccines (57% BNT162b2; 6 175 813 first doses and 5 669 315 second doses) were administered to 6.2 million individuals (mean age, 49 years; 54% female individuals). The incidence of events per 1 000 000 person-years during the risk vs comparison intervals for ischemic stroke was 1612 vs 1781 (RR, 0.97; 95% CI, 0.87-1.08); for appendicitis, 1179 vs 1345 (RR, 0.82; 95% CI, 0.73-0.93); and for acute myocardial infarction, 935 vs 1030 (RR, 1.02; 95% CI, 0.89-1.18). No vaccine-outcome association met the prespecified requirement for a signal. Incidence of confirmed anaphylaxis was 4.8 (95% CI, 3.2-6.9) per million doses of BNT162b2 and 5.1 (95% CI, 3.3-7.6) per million doses of mRNA-1273.In interim analyses of surveillance of mRNA COVID-19 vaccines, incidence of selected serious outcomes was not significantly higher 1 to 21 days postvaccination compared with 22 to 42 days postvaccination. While CIs were wide for many outcomes, surveillance is ongoing." @default.
• W3197830587 created "2021-09-13" @default.
• W3197830587 creator A5000635762 @default.
• W3197830587 creator A5006415074 @default.
• W3197830587 creator A5006442640 @default.
• W3197830587 creator A5006755486 @default.
• W3197830587 creator A5016019091 @default.
• W3197830587 creator A5027252901 @default.
• W3197830587 creator A5030551838 @default.
• W3197830587 creator A5034478332 @default.
• W3197830587 creator A5037443507 @default.
• W3197830587 creator A5040276088 @default.
• W3197830587 creator A5040342415 @default.
• W3197830587 creator A5049218359 @default.
• W3197830587 creator A5053590091 @default.
• W3197830587 creator A5059023087 @default.
• W3197830587 creator A5065809957 @default.
• W3197830587 creator A5071176605 @default.
• W3197830587 creator A5079380283 @default.
• W3197830587 creator A5081321979 @default.
• W3197830587 creator A5088198148 @default.
• W3197830587 date "2021-10-12" @default.
• W3197830587 modified "2023-10-14" @default.
• W3197830587 title "Surveillance for Adverse Events After COVID-19 mRNA Vaccination" @default.
• W3197830587 cites W1918065319 @default.
• W3197830587 cites W1970143540 @default.
• W3197830587 cites W1996163175 @default.
• W3197830587 cites W2042322297 @default.
• W3197830587 cites W2046085703 @default.
• W3197830587 cites W2098104511 @default.
• W3197830587 cites W2120727179 @default.
• W3197830587 cites W2127151679 @default.
• W3197830587 cites W2130219862 @default.
• W3197830587 cites W2985760482 @default.
• W3197830587 cites W3007464632 @default.
• W3197830587 cites W3038345433 @default.
• W3197830587 cites W3111255098 @default.
• W3197830587 cites W3111642148 @default.
• W3197830587 cites W3113879463 @default.
• W3197830587 cites W3114735216 @default.
• W3197830587 cites W3120968995 @default.
• W3197830587 cites W3128551684 @default.
• W3197830587 cites W3130815000 @default.
• W3197830587 cites W3131650037 @default.
• W3197830587 cites W3134831990 @default.
• W3197830587 cites W3152102956 @default.
• W3197830587 cites W3157466234 @default.
• W3197830587 cites W3157488589 @default.
• W3197830587 cites W3159001141 @default.
• W3197830587 cites W3165142255 @default.
• W3197830587 cites W3167640233 @default.
• W3197830587 cites W3179690832 @default.
• W3197830587 cites W3187606327 @default.
• W3197830587 cites W4205483821 @default.
• W3197830587 cites W4249999102 @default.
• W3197830587 doi "https://doi.org/10.1001/jama.2021.15072" @default.
• W3197830587 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8511971" @default.
• W3197830587 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34477808" @default.
• W3197830587 hasPublicationYear "2021" @default.
• W3197830587 type Work @default.
• W3197830587 sameAs 3197830587 @default.
• W3197830587 citedByCount "393" @default.
• W3197830587 countsByYear W31978305872021 @default.
• W3197830587 countsByYear W31978305872022 @default.
• W3197830587 countsByYear W31978305872023 @default.
• W3197830587 crossrefType "journal-article" @default.
• W3197830587 hasAuthorship W3197830587A5000635762 @default.
• W3197830587 hasAuthorship W3197830587A5006415074 @default.
• W3197830587 hasAuthorship W3197830587A5006442640 @default.
• W3197830587 hasAuthorship W3197830587A5006755486 @default.
• W3197830587 hasAuthorship W3197830587A5016019091 @default.
• W3197830587 hasAuthorship W3197830587A5027252901 @default.
• W3197830587 hasAuthorship W3197830587A5030551838 @default.
• W3197830587 hasAuthorship W3197830587A5034478332 @default.
• W3197830587 hasAuthorship W3197830587A5037443507 @default.
• W3197830587 hasAuthorship W3197830587A5040276088 @default.
• W3197830587 hasAuthorship W3197830587A5040342415 @default.
• W3197830587 hasAuthorship W3197830587A5049218359 @default.
• W3197830587 hasAuthorship W3197830587A5053590091 @default.
• W3197830587 hasAuthorship W3197830587A5059023087 @default.
• W3197830587 hasAuthorship W3197830587A5065809957 @default.
• W3197830587 hasAuthorship W3197830587A5071176605 @default.
• W3197830587 hasAuthorship W3197830587A5079380283 @default.
• W3197830587 hasAuthorship W3197830587A5081321979 @default.
• W3197830587 hasAuthorship W3197830587A5088198148 @default.
• W3197830587 hasBestOaLocation W31978305871 @default.
• W3197830587 hasConcept C120665830 @default.
• W3197830587 hasConcept C121332964 @default.
• W3197830587 hasConcept C126322002 @default.
• W3197830587 hasConcept C127413603 @default.
• W3197830587 hasConcept C142724271 @default.
• W3197830587 hasConcept C187212893 @default.
• W3197830587 hasConcept C194828623 @default.
• W3197830587 hasConcept C203014093 @default.
• W3197830587 hasConcept C204787440 @default.
• W3197830587 hasConcept C22070199 @default.
• W3197830587 hasConcept C2776494729 @default.
• W3197830587 hasConcept C2780645631 @default.

• next